Summary: As this is an open label study, all patients will receive SDX-105 by 30-60 minute intravenous infusion on day 1 and day 2. Treatment will repeat every 21 days. Treatment can continue for up to one year in the absence of disease progression or unacceptable toxicity. Patients will be followed until disease progression. Rationale: Drugs used in chemotherapy, such as SDX-105, use different ways to stop tumor cells from dividing so they stop growing or die. Purpose: This study will evaluate the effectiveness and safety in non-Hodgkin's lymphoma in patients who are refractory to Rituxan.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
72
University of Alabama at Birmingham
Birmingham, Alabama, United States
Comprehensive Cancer Center-Desert Regional Medical Center
Palm Springs, California, United States
San Diego Cancer Center
Vista, California, United States
Georgetown University Medical Center - Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Mountain States Tumor Institute
Boise, Idaho, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
The Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of Rochester Medical Center
Rochester, New York, United States
The Sarah Cannon Cancer Center
Nashville, Tennessee, United States
...and 7 more locations
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.